Haleon plc 6-K, filed Nov 2, 2026
Haleon plc (HLN)
6-K
2026-11-02
For: 2026-11-02
View Original
Added on
November 02, 2026
About this 6-K
Haleon plc filed this 6-K on November 2, 2026.
As at 31 October 2026, Haleon plc had issued 8,808,341,409 ordinary shares of £0.01 each, including 16,238,543 treasury shares, leaving 8,792,102,866 ordinary shares with voting rights. AI summary
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2026
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
02
November 2026 - “Total Voting
Rights and Capital”
|
99.1
Haleon plc: Total Voting Rights and Capital
02 November 2026: As at 31 October 2026 the total
number of shares issued by Haleon plc (“Haleon” or the
“Company”) is 8,808,341,409 ordinary shares of
£0.01 each, of which 16,238,543 are held as treasury
shares.
Therefore, the number of ordinary shares with voting rights is
8,792,102,866 and this figure should be used by shareholders (and
others with notification obligations) as the denominator for the
calculation by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
Company under the FCA's Disclosure Guidance and Transparency
Rules.
Notifiable interests in Haleon may be sent to: company.secretary@haleon.com
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused
on better everyday health. Our people, our brands, our research,
our investment and our innovation are aimed at improving the
everyday health of consumers. Our product portfolio spans six major
categories - Oral Health, Vitamins, Minerals and Supplements (VMS),
Pain Relief, Respiratory Health, Digestive Health and Therapeutic
Skin Health and Other. Our superior brands - such as
Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are trusted by more than one billion
consumers and are recommended by health professionals around the
world.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date:
November 02, 2026
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|